Скачать или смотреть Assessing treatment efficacy in MS and NMOSD: moving beyond relapse rates

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses the challenges of assessing treatment efficacy in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) due to the low relapse rates achieved with current high-efficacy treatments. Prof. Oreja-Guevara highlights the need to explore alternative outcomes beyond relapses, such as digital technologies, biomarkers like neurofilaments, and optical coherence tomography. This interview took place at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.